FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin
Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017
Humanitarian Factor IX donation to Afghanistan
Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries
Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment
BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017
SIPPET Study: interim analysis confirms the original hypothesis
The Study on inhibitors in Hemophilia A is safe to continue after Investigators’ Meeting in San Francisco (Dec 2014)
Investigating inhibitor development in patients with Hemophilia A
Lecture on state-of-the-art of the SIPPET Study presented by P.M. Mannucci, sponsored by Grifols, Kedrion and LFB
Counterfeit RhoGAM Ultra-Filtered PLUS used for preventing HDN found in India
Johnson & Johnson Limited has identified counterfeit RhoGAM Ultra-Filtered PLUS in the state of West Bengal and Uttar Pradesh in India. This issue does not involve any other product manufactured or distributed by Ortho Clinical Diagnostics or Kedrion Biopharma India Pvt. Ltd.
Kedrion collection centers first to be certified in Hungary
Plazmaferezis Állomás Kft achieves international PPTA certification
Distribution of the first recombinant Factor VIII from human cells
Kedrion to be the distributor in Italy over the next ten years. The indication is the treatment of…
Kedrion presents the new Factor VIII for the Hungarian market
Today, at the Hungarian Academy of Sciences in Budapest, a scientific symposium celebrated the launch on the Hungarian market of the new plasma-derived product Factor VIII by Human BioPlazma, Kedrion Group’s Budapest-based subsidiary, which runs the production plant of Gödöllő. Manufactured at the production plant of Bolognana through the purification of an intermediate product received
Agreement with Entegrion for the development and marketing of Resusix™, a virus inactivated spray-dried plasma
Kedrion Melville Inc., a US-based company owned by Kedrion, entered into an agreement with the US-based company Entegrion Inc. for the development and marketing of Resusix™, a virus inactivated spray-dried plasma, treated with solvent-detergent, to be used as a replacement of frozen fresh plasma. The Phase-I clinical trials that have recently been authorised by the